PureTech Health (LON:PRTC) Earns Buy Rating from Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of PureTech Health (LON:PRTC) in a research note released on Monday morning, MarketBeat Ratings reports. They currently have a GBX 455 ($5.77) target price on the stock.

PureTech Health Stock Performance

Shares of PRTC opened at GBX 170 ($2.16) on Monday. The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68. PureTech Health has a twelve month low of GBX 138.75 ($1.76) and a twelve month high of GBX 238.50 ($3.03). The firm’s 50 day moving average price is GBX 161.22 and its two-hundred day moving average price is GBX 171. The firm has a market cap of £407.01 million, a P/E ratio of -739.13 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.